C12Y 304/22059
Caspase-6
Official title: Caspase-6 (3.4.22.59)
C12Y304/22059 (Caspase-6) appears on 3 US grants and 8 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 8
- Assignees
- 7
- Inventors
- 22
- Latest grant
- 15 Dec 2015
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 2 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
By publication year.
Recent patents
- Method for the determination of botulinum neurotoxin biological activity15 Dec 2015US 9,212,355 B2MERZ PHARMA GmbH & CO. KGaA
- Method for the determination of botulinum neurotoxin biological activity4 Aug 2015US 9,096,886 B2MERZ PHARMA GmbH & CO. KGaA
- Antisense modulation of caspase 6 expression20 May 2003US 6,566,135 B1Isis Pharmaceuticals, Inc.
- Gene expression cassette for expressing n-terminal methionine-truncated protein of interest and method for producing n-terminal methionine-truncated protein of interest by using same21 Apr 2022US 2022/0119792 A1Polus LLC
- Intranasal Delivery of Cell Permeant Therapeutics28 May 2020US 2020/0164026 A1Sanford-Burnham Medical Research Institute
- Methods of treating alzheimer's disease9 Jan 2020US 2020/0009180 A1Ramot at Tel-Aviv University Ltd.
- Method for the determination of botulinum neurotoxin biological activity8 Oct 2015US 2015/0284702 A1MERZ PHARMA GmbH & CO. KGaA
- Intranasal delivery of cell permeant therapeutics23 Jan 2014US 2014/0024597 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents